Pulse Biosciences Reports $434K Product Revenue in Q2 2026, Net Loss of $24.7M

Pulse Biosciences, Inc. reported its financial results for the second quarter of 2026, revealing a product revenue of $434,000, a significant increase from zero revenue in the same period last year. For the first half of 2026, total product revenue reached $835,000, attributed to the limited market release of the Vybrance Percutaneous Electrode System. Despite this revenue generation, the company incurred a net loss of $24.7 million for the quarter, compared to a loss of $19.2 million in the prior year, and a total net loss of $43.2 million for the first half of 2026, up from $36.0 million in the same period of 2025.

The company's total expenses for the second quarter amounted to $25.7 million, an increase from $20.3 million in the previous year. This rise was primarily driven by a $4.9 million increase in research and development expenses, which totaled $17.0 million for the quarter, reflecting heightened investment in clinical research and personnel costs. Selling, general, and administrative expenses also saw a slight increase to $8.5 million, up from $8.2 million year-over-year. The company’s accumulated deficit reached $506.5 million as of June 30, 2026.

In terms of strategic developments, Pulse Biosciences announced a realignment in March 2026 to focus on the development of its nsPFA electrophysiology catheters and other cardiac devices for treating atrial fibrillation (AF). This decision followed positive clinical data from its first-in-human feasibility study of the nPulse Cardiac Catheter System. The company is also pursuing additional clinical trials and has received FDA approval for its Investigational Device Exemption (IDE) to conduct a pivotal study for the catheter system.

Operationally, Pulse Biosciences reported a cash and cash equivalents balance of $101.6 million as of June 30, 2026, an increase from $80.7 million at the end of 2025. The company raised $46.8 million through its at-the-market offering program during the first half of 2026. The employee headcount remained stable, with ongoing investments in research and development to support its product lines. The company continues to face challenges in achieving profitability, with expectations of incurring additional losses in the coming years as it invests in product development and market expansion.

Looking ahead, Pulse Biosciences remains focused on advancing its nsPFA technology and expanding its market presence in the electrophysiology sector. The company anticipates that its existing financial resources will be sufficient to support operations for at least the next year, although it plans to seek additional capital to fund ongoing development efforts. The outlook remains cautious, with potential risks related to market conditions and the need for further financing to sustain its business objectives.